CHERISH Events

Conference Roundup: CPDD 85th Annual Scientific Meeting

A curated list of appearances featuring CHERISH researchers.

June 17-21, 2023

CPDD 85th Annual Scientific Meeting, Denver, CO

Connect with CHERISH investigators, CHERISH Research Affiliates, and Advisory Board members in person as they present their research at #CPDD23.

The official time zone of the conference is Mountain Time (MDT). View the full program here.

Sunday, June 18, 2023

  • Lindsay Allen, PhD, MA, Feinberg School of Medicine at Northwestern University
    • S85 Pharmacy-Level Barriers to Buprenorphine Dispensing: Evidence From the Medicaid Distributed Research Network in Five States, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Joshua Barocas, MD, University of Colorado School of Medicine
    • Identifying Structural Risk Factors for Overdose Following Incarceration: A Concept Mapping Study, 10:30 AM – 10:45 AM at Plaza Ballroom D, Author
  • Peter Friedmann, MD, MPH, FASAM, FACP, University of Massachusetts Medical School, Baystate Health
    • Recent Incarceration, Substance Use, Overdose, and Treatment Among Rural People who Use Drugs, 10:45 AM – 11 AM at Plaza Ballroom D, Author
    • S135 Differences in Hepatitis C Virus (HCV) Testing and Treatment by Opioid, Stimulant, and Polysubstance Injection Among People who Inject Drugs (PWID) in Rural U.S. Communities, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Yih-Ing Hser, PhD, CHERISH Center Advisor, Integrated Substance Abuse Programs, University of California, Los Angeles
    • S54 Social Determinants of Health and Quality of Care Among Patients With Opioid Use Disorder Receiving Treatment in Rural Primary Care Settings, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • S81 Factors Associated With Patient Referral From Rural Primary Care Clinics to Vendor-Based Telemedicine for Opioid Use Disorder Treatment, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • S145 The Potential of Virtual Reality to Treat Substance Use Disorders, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Ali Jalali, PhD, MA, Weill Cornell Medicine
    • Jail-Based Medication for Opioid Use Disorder and Patterns of Community Re-Entry after Release: A Sequence Analysis, 10:15 AM – 11:45 AM at Plaza Ballroom D, Author
  • Noa Krawczyk, PhD, NYU Grossmal School of Medicine
    • Jail-Based Medication for Opioid Use Disorder and Patterns of Community Re-Entry after Release: A Sequence Analysis, 10:15 AM – 10:30 AM at Plaza Ballroom D, Author
    • S45 Transition Strategies to Link Patients With Substance Use Disorders From Acute Care to Community-Based Treatment Settings: A Scoping Review, 5:15 PM – 6:45 PM at Plaza Exhibit, Presenter
  • Benjamin Linas, MD, MPH, Director, Population Data & Modeling Core, Boston Medical Center
    • S47 Trends in Buprenorphine Dosage and Days Supplied for New Treatment Episodes, 2010-2019, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Alain Litwin, MD, University of South Carolina School of Medicine Greenville
    • S72 The Association of Self-Report Adherence to Hepatitis C (HCV) Direct-Acting Antiviral (DAA) Therapy With Measured Adherence and Sustained Virologic Response Among People Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Lisa Marsch, PhD, CHERISH Center Advisor, Director, Center for Technology and Behavioral Health, Dartmouth College
    • S96 The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Thomas McLellan, PhD, University of Pennsylvania Perelman School of Medicine
    • Workshop: “Pre-Addiction:” A Starting Point for a Strategic Shift Toward Earlier Intervention in Substance Use Disorders, 2:15 PM – 3:45 PM at Plaza Ballroom BCEF (Plenary), Discussant
  • Sean Murphy, PhD, Co-director, Methodology Core, Director, CHERISH Consultation Service, Weill Cornell Medicine
    • Jail-Based Medication for Opioid Use Disorder and Patterns of Community Re-Entry after Release: A Sequence Analysis, 10:15 AM – 10:30 AM at Plaza Room D, Author
  • Jeffrey Samet, MD, MPH, MA, CHERISH Center Advisor, Director, Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH), Boston Medical Center
    • S47 Trends in Buprenorphine Dosage and Days Supplied for New Treatment Episodes, 2010-2019, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • S95 Mobile Units Improve Access to Medications for Opioid Use Disorder: A Qualitative Implementation Study, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • S113 Provider Perspectives on Facilitators and Barriers to Providing HIV Pre-Exposure Prophylaxis (PrEP) in Hospital-Based Addiction Treatment Bridge Clinics to Women Sex Workers who Use Drugs, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Jeffery Talbert, PhD, MA, University of Kentucky
    • S85 Pharmacy-Level Barriers to Buprenorphine Dispensing: Evidence From the Medicaid Distributed Research Network in Five States, 5:15 PM – 6:45 at Plaza Exhibit, Author
  • Alexander Walley, MD, MSc, Investigator, Population Data & Modeling Core, Boston Medical Center
    • S113 Provider Perspectives on Facilitators and Barriers to Providing HIV Pre-Exposure Prophylaxis (PrEP) in Hospital-Based Addiction Treatment Bridge Clinics to Women Sex Workers who Use Drugs, 5:15 PM – 6:45 PM at Plaza Exhibit, Author

Monday, June 19, 2023

  • Ahmed Bayoumi, MD, MSc, St. Michael’s Hospital, University of Toronto
    • M106 Reduction in Substance Use-Related Harms Among a Cohort of People Receiving Injectable Opioid Agonist Treatment in Ontario, Canada, 5 PM – 6:30 PM at Plaza Exhibit, Author
  • Alain Litwin, MD, University of South Carolina School of Medicine Greenville
    • Exploration of HIV Risk Behaviors and Attitudes Towards PrEP Among People who Inject Drugs by Gender and Sexual Orientation, 3:30 PM – 3:45  PM at Governor’s Square 15, Author
    • M132 Depression Profiles and Hepatitis C Treatment Outcomes Among Persons who Inject Drugs: The Hero Study, 5 PM – 6:30 PM at Plaza Exhibit, Author
  • James McKay, PhD, CHERISH Center Advisor, Director, Penn-TRI Center on the Continuum of Care in the Addictions, University of Pennsylvania
    • M95 Early Non-Adherence Among Individuals Initiating Low Barrier Buprenorphine Treatment in an Office-Based Setting, 5 PM – 6:30 PM at Plaza Exhibit, Author
  • Brendan Saloner, PhD, Johns Hopkins Bloomberg School of Public Health
    • M148 State Licensure Policy as an Innovative Tool for Mainstreaming Medications for Opioid Use Disorder, 5 PM – 6:30 PM at Plaza Exhibit, Author
    • M149 Attitudes and Beliefs About Vermont’s 2021 Buprenorphine Decriminalization Law Among Residents who Use Illicit Opioids, 5 PM – 6:30 PM at Plaza Exhibit, Author
  • Jeffery Talbert, PhD, University of Kentucky
    • M121 Opioid-Related Poisoning in Kentucky Medicaid Beneficiaries Receiving Buprenorphine, Methadone or Naltrexone, 5 PM – 6:30 PM at Plaza Exhibit, Author
  • Cindy P. Thomas, PhD, Brandeis University Heller School for Social Policy and Management
    • M142 Opioid Use Disorder Treatment in Medicaid Managed Care Plans, 5 PM – 6:30 PM at Plaza Exhibit, Author

Tuesday, June 20, 2023

  • Sabrina A. Assoumou, MD, MPH, Boston Medical Center
    • T152 HIV and Hepatitis C Virus-Related Misinformation Remains a Challenge to Improved Clinical Outcomes Among Persons who use Drugs During the U.S. Opioid Overdose Crisis, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Ahmed Bayoumi, MD, MSc, St. Michael’s Hospital, University of Toronto
    • T58 Initiations of Safer Supply Hydromorphone Increased During the COVID-19 Pandemic in Ontario: An Interrupted Time-Series Analysis, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Annick Bórquez, PhD, University of California San Diego
    • T95 A Time Series Analysis of Nonfatal and Fatal Drug Overdose Outcomes for the Surveillance of Drug Overdose Outbreaks, 5:15 PM – 6:45 PM at Plaza Exhibit, Presenter
  • Robin E. Clark, PhD, MA, University of Massachusetts Medical School
    • T105 Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-Site Study in Eight U.S. Health Systems, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Michael L. Dennis, PhD, Chestnut Health Systems
    • T156 Momentary Latent Class Membership to Predict Self-Efficacy and Subsequent Substance Use, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Rachel Epstein, MD, MSc, Boston Medical Center
    • T53 Disparities in the Hepatitis C Virus Cascade of Care Among Reproductive Age Women With Opioid Use Disorder, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Daniel Feaster, PhD, University of Miami Miller School of Medicine 
    • T163 Latent Class Analysis of Psychosocial Factors Among People Living with HIV who Use Substances, 5:15 PM – 6:45 PM at Plaza Exhibit, Presenter
  • Peter Friedmann, MD, MPH, FASAM, FACP, University of Massachusetts Medical School, Baystate Health
    • T106 Barriers to Retention in Inpatient and Residential Drug Treatment Among Persons who Use Opioids in the Rural U.S., 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Yih-Ing Hser, PhD, CHERISH Center Advisor, Integrated Substance Abuse Programs, University of California, Los Angeles
    • T142 Polysubstance Use Among Patients With Opioid Use Disorder in Rural Primary Care Clinics, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Ali Jalali, PhD, MA, Weill Cornell Medicine
    • T72 Impact of Medication-Based Treatment on Healthcare Utilization Among Individuals With Opioid Use Disorder: A Secondary Analysis of the X:BOT Clinical Trial, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Lisa Marsch, PhD, CHERISH Center Advisor, Director, Center for Technology and Behavioral Health, Dartmouth College
    • T36 Feasibility and Acceptability of an Ecological Momentary Intervention of Implementation Intentions Delivered by Text Message to Reduce Cigarette Smoking, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • T102 Understanding the Needs of Women in Treatment for Opioid Use Disorder to Inform the Development of a Gender-Specific Digital Intervention, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Brandon Marshall, PhD, Brown University School of Public Health
    • T87 Long-Term Relationship Between Opioid Use and Change in HIV Disease Severity: A Prospective Cohort Study, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Sean Murphy, PhD, Co-director, Methodology Core, Director, CHERISH Consultation Service, Weill Cornell Medicine
    • T72 Impact of Medication-Based Treatment on Healthcare Utilization Among Individuals With Opioid Use Disorder: A Secondary Analysis of the X:BOT Clinical Trial, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Jeffrey Samet, MD, MPH, MA, CHERISH Center Advisor, Director, Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH), Boston Medical Center
    • T101 The Primary Care Opioid Use Disorders Treatment (PROUD) Trial, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Thomas Stopka, PhD, MHS, Tufts University School of Medicine
    • T99 Perceptions of Syndromic Surveillance to Prevent Overdose in Lowell, Massachusetts: Qualitative Perspectives of Community Leaders and People who Use Drugs, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
    • T106 Barriers to Retention in Inpatient and Residential Drug Treatment Among Persons who Use Opioids in the Rural U.S., 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Jeffery Talbert, PhD, University of Kentucky
    • T97 Policies Relevant to the Healing Communities Study Kentucky Site Implementation, 5:15 PM – 6:45 PM at Plaza Exhibit, Author
  • Alexander Walley, MD, MSc, Investigator, Population Data & Modeling Core, Boston Medical Center
    • T62 An Emulated Trial of Buprenorphine-Naloxone Versus Extended-Release Naltrexone Following Medically Managed Opioid Withdrawal, 5:15 PM – 6:45 PM at Plaza Exhibit, Author

Wednesday, June 21, 2023

  • Joshua Barocas, MD, University of Colorado School of Medicine
    • National Trends in Methamphetamine-Related Psychiatric Hospitalizations in the United States, 2015-2019, 8:15 AM – 8:30 AM at Plaza Ballroom A, Author
  • Brittany Bass, PhD, UCLA Integrated Substance Abuse Programs
    • W127 Supportive Services Program Utilization Among Substance Use Treatment Clients Using Big Data, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Ahmed Bayoumi, MD, MSc, St. Michael’s Hospital, University of Toronto
    • W54 Frequency of Fentanyl Injection is Associated with Hepatitis C Status: A Cross-Sectional Study, 2 PM – 3:30 PM at Plaza Exhibit, Presenter
  • Annick Bórquez, PhD, University of California San Diego
    • W112 Drug Checking in the Fentanyl Era: Awareness, Interest, and Utilization Among People who Inject Drugs in San Diego County, California, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Daniel Feaster, PhD, University of Miami Miller School of Medicine 
    • High Suicidality Predicts Overdose Events Among People With Substance Use Disorder: A Latent Class Analysis, 3:45 PM – 4 PM at Grand Ballroom I, Author
    • Symposium: A Gentle Introduction to Data Science Tools for Addiction Research: Use Cases With Examples, 10 AM – 11:30 AM at Plaza Ballroom A, Discussant
    • W122 Diabetes Management in Patients With Substance Use Disorder Served in a Network of Federally Qualified Health Centers in Florida: A Retrospective Analysis Using EHR Data, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W137 Prep Experience and Willingness in Substance-Using MSM in Higher Incidence Southern U.S. Cities: NIDA Clinical Trials Network Study, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W138 PrEP and PEP Experience and Willingness in People who Use Opioids: A NIDA Clinical Trials Network Study in Southern U.S. Cities Where HIV Incidence Is High, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Daniel Hartung, PharmD, MPH, Oregon State University
    • W65 Trends in Buprenorphine Prescribing in a National Network of Community Health Centers, 2 PM – 3:30 PM at Plaza Exhibit, Presenter
  • Yih-Ing Hser, PhD, CHERISH Center Advisor, Integrated Substance Abuse Programs, University of California, Los Angeles
    • W105 Exploring the Impact of the COVID-19 Pandemic on MOUD Retention in a Sample of Rural Primary Care Patients, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W145 Rates of Medication Prescription, Mental Health Disorder, and HCV Diagnoses Among Patients With Comorbid Alcohol and Opioid Use Disorder in Rural Primary Care Clinics, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Mohammad Jalali, PhD, MSc, Harvard Medical School
    • W43 The Impact of CDC’s Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Noa Krawczyk, PhD, NYU Grossman School of Medicine
    • W63 Impact of Covid-Related Policy Changes on Retention and Adverse Events Amongst new Methadone Maintenance Intakes, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Lisa Marsch, PhD, CHERISH Center Advisor, Director, Center for Technology and Behavioral Health, Dartmouth College
    • W93 The Relationship between Substance Use and Remote Hiv Testing among Men at Risk for HIV, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Brandon Marshall, PhD, Brown University School of Public Health
    • W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Brendan Saloner, PhD, Johns Hopkins Bloomberg School of Public Health
    • W40 High Threshold Prescribing Practices Associated with Increased Termination of Care: Results From a Survey of Michigan Buprenorphine Prescribers, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Jeffrey Samet, MD, MPH, MA, CHERISH Center Advisor, Director, Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH), Boston Medical Center
    • W53 Socioeconomic Status and HIV Severity Among People With HIV who Inject Drugs in St. Petersburg, Russia, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W146 Is Abstinence From Alcohol and Smoking Associated With Better Mood Among People With HIV?, 2 PM – 3:30 PM at Plaza Exhibit, Author
  • Alexander Walley, MD, MSc, Investigator, Population Data & Modeling Core, Boston Medical Center
    • W39 Self-Reported Opioid Overdose via 120-Day Timeline Follow-Back and Documented Overdose Medical Encounters Among Opioid Overdose Survivors, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W55 Fentanyl Route of Administration and Overdose Risk: A Preliminary Analysis of Baseline Data From a Cohort of Overdose Survivors in San Francisco and Boston, 2 PM – 3:30 PM at Plaza Exhibit, Author
    • W95 Hopelessness and Impulsivity and Recent Non-Fatal Overdose Among Overdose Survivors who Actively Use Nonprescribed Opioids in San Francisco and Boston, 2 PM – 3:30 PM at Plaza Exhibit, Author